Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MRNA stock is seen purely as a Covid-19 play. Until Moderna can prove it's not a one-hit wonder, shares are likely to remain depressed.

Is Moderna the Next Gilead or the Next Regeneron?

Pfizer

Planning is still in early stages and authorization would depend on resolving several issues, the Wall Street Journal reported

FDA Reportedly Mulling Approving Second Covid Booster Shot

Bath and Body Works

Devon Energy

Ford Motor Company

Gartner

NVIDIA

Simon Property Group

Most of the S&P 500 were momentum stocks in 2021. In 2022, they're not doing nearly as well.

7 Momentum Stocks to Buy While the Market Corrects

MercadoLibre

PayPal

Their businesses continue to make lots of money. And analysts think the stocks could make investors a lot of money, too.

3 Highly Profitable Stocks to Buy That Wall Street Thinks Can Soar 80% to 90%

It has to do with the next stage of the health crisis.

1 Crucial Thing to Look For in Moderna's Earnings Report

Ceridian HCM Holding Inc.

DexCom

EPAM Systems

Etsy

Netflix

Teradyne

Zebra Technologies

The S&P 500 is off almost 9% for the year-to-date, but the biggest decliners in the main benchmark of U.S. equity performance are faring far, far worse. From small, somewhat obscure members of the index to the planet's best-known and biggest stocks, the S&P 500's most beaten-down names do have at least a few commonalities.

10 Biggest Losers in the S&P 500 This Year

Microsoft

Exxon Mobil

Capital is key for investing. Sadly, many retail investors can only master a small account.

Small retail investing strategy – Top high growth stocks to follow

DraftKings

Peloton

Zoom Video

Bitcoin (BTC) continues to get all the negative attention for its recent poor performance, which saw the flagship crypto fall more than 50% from its peak in November. But stocks have had it even worse and the following 5 large-cap stocks all post over 60% in losses since their 52-week highs.

5 stocks hammered more than Bitcoin from their 52-week highs

Moderna Inc (NASDAQ: MRNA) said it is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection shingles. The success of COVID-19 vaccines based on messenger RNA (mRNA) technology from Moderna and rival Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) has prompted efforts to use the novel technology in other vaccines and therapeutics.

Moderna Adds Three New mRNA-Based Development Programs To Its Pipeline

Moderna Inc said on Friday it is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection shingles.

Moderna to develop mRNA-based shingles vaccine

Shares of Moderna Inc. MRNA, -3.59% gained 0.1% on Friday after the company said it is now developing mRNA vaccines for herpes simplex virus, varicella-zoster virus (against shingles), and certain types of cancer, starting with advanced or metastatic melanoma and non-small cell lung carcinoma. The company's stock is down 13.7% over the past year, while the broader S&P 500 SPX, -2.12% is 11.4%.

Moderna to develop three new mRNA vaccine candidates

mRNA-1608 is a vaccine candidate against Herpes simplex virus (HSV) mRNA-1468 is a vaccine candidate against varicella-zoster virus (VZV) to reduce the rate of herpes zoster (shingles) mRNA-4359 is a new checkpoint cancer vaccine CAMBRIDGE, MA / ACCESSWIRE / February 18, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its mRNA pipeline with three new development programs. This announcement reflects the Company's commitment to expanding its portfolio building on Moderna's experience with Spikevax®, its COVID-19 vaccine.

Moderna Expands Its mRNA Pipeline with Three New Development Programs

Moderna Inc's (NASDAQ: MRNA) CEO, Stephane Bancel, told Reuters that an omicron-specific booster could be ready by August. The CEO said that the firm is still gathering clinical data to determine whether that vaccine would offer better protection than a new dose of the existing jab.

Moderna Says COVID-19 Booster To Be Ready By August, But Dicey If Omicron-Specific Needed: Reuters

Pfizer's billion-dollar mRNA vaccine could be just the beginning.

2 Reasons Why Pfizer Might Crush Moderna in the mRNA Market. And 1 Reason Why Moderna May Stay Ahead.

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

They're already bringing in billions of dollars in revenue.

3 Top Biotech Stocks to Buy for the Long Haul

CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a 50 µg dose, two-dose series, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6-11 years. "The TGA authorization for the use of our COVID-19 vaccine in children 6-11 years old in Australia is an important milestone for Moderna as it is the first regulatory authorization for the use of our vaccine in this age group.

Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)

Announcement reinforces Moderna's commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific region Local commercial presence to be established in Belgium, Denmark, the Netherlands, Norway, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to expand its commercial network across six additional countries in Europe. Moderna plans to establish a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics locally.

Moderna Announces Plan to Expand Commercial Footprint in Europe Across Six Additional Countries

CEO Stephane Bancel says he thinks the end of the Covid-19 pandemic is a 'reasonable scenario.'

Moderna CEO Says End of Pandemic Is Nearing

Moderna stock has declined by almost 40% thus far in 2022 and currently trades at about $142 per share. The sell-off is driven by a couple of factors.

At $140, Moderna Stock Is A Solid Value Bet

Spain's Laboratorios Farmaceuticos Rovi SA has agreed on a 10-year extension to its deal with Moderna Inc (NASDAQ: MRNA) to manufacture future drugs developed with the mRNA technology used for its COVID-19 shot. The new agreement includes a series of investments expected to increase manufacturing capacity across ROVI's facilities in Madrid, Spain.

Moderna-Rovi Seal 10-Year Deal Extension To Make mRNA Drugs

Stéphane Bancel believes there's about an 80% chance that the virus causing COVID-19 will get less virulent, but cautioned it remains "unpredictable."

Moderna's CEO says it's 'reasonable' to suggest the COVID-19 pandemic is in its final stages

The tide has turned for this once high-flying vaccine stock.

Why It's Time to Buy Moderna Stock Again

Moderna CEO Says End of Covid-19 Pandemic Is Approaching

“I think that's a reasonable scenario.”

Key Words: The end of the pandemic may be in sight, says Moderna CEO

"I think that is a reasonable scenario," Moderna's CEO Stephane Bancel said when asked about the whether the Covid-19 pandemic may now be in its final stages.

News for Moderna Stock (MRNA)